This analysis from EP Vantage offers a round-up of the most valuable R&D assets, based on EvaluatePharma consensus forecasts.

After the recent approvals of Merck & Co's Keytruda and Bristol-Myers Squibb's Opdivo, attention has shifted to what might now represent the industry's most-valuable development stage assets.

Download the article to read more about:

• Most valuable phase III assets

• Most valuable assets awaiting regulatory approval

• Major oncology assets

• Pipeline value (NPV) by therapy area

To download this article, please confirm your details on the form opposite.